Metabolism and action of proteasome inhibitors in primary human hepatocytes

Drug Metabolism and Disposition

Volumn 38, Issue 12, 2010, Pages 2166-2172

  Lee, Choon Myung ^a   Kumar, Vikas ^b   Riley, Rochelle I ^b   Morgan, Edward T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CYTOCHROME P450; CYTOCHROME P450 3A; CYTOKINE; EPOXOMICIN; KETOCONAZOLE; LACTACYSTIN; NITRIC OXIDE; PHENOBARBITAL; PROTEASOME INHIBITOR; RIFAMPICIN;

ADOLESCENT; ADULT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG STABILITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; LIVER CELL; MALE; PRIORITY JOURNAL;

EID: 78649594723     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035501     Document Type: Article

References (27)

1. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, and Stein RL (1998) Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 8:333-338.
2. Aitken AE, Lee CM, and Morgan ET (2008) Roles of nitric oxide in inflammatory downregulation of human cytochromes P450. Free Radic Biol Med 44:1161-1168.
3. Barnes PJ and Karin M (1997) Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071.
4. i and dangers associated with high clearance drugs in general. J Pharm Pharm Sci 2:47-52.
5. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, Nunes SL, Palombella VJ, Parent LA, Plamondon L, et al. (1997) Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 272:182-188.
6. Dick LR, Cruikshank AA, Grenier L, Melandri FD, Nunes SL, and Stein RL (1996) Mechanistic studies on the inactivation of the proteasome by lactacystin: a central role for clasto-lactacystin β-lactone. J Biol Chem 271:7273-7276.
7. Ghosal A, Satoh H, Thomas PE, Bush E, and Moore D (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940-947.
8. Goodwin B, Hodgson E, and Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329-1339.
9. 15N]nitrate in biological fluids. Anal Biochem 126:131-138.
10. Guengerich FP (2004) Cytochrome P450: what have we learned and what are the future issues? Drug Metab Rev 36:159-197.
11. Kikuchi S, Shinpo K, Tsuji S, Takeuchi M, Yamagishi S, Makita Z, Niino M, Yabe I, and Tashiro K (2003) Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons. Brain Res 964:228-236.
12. Lee CM, Kim BY, Li L, and Morgan ET (2008) Nitric oxide-dependent proteasomal degradation of cytochrome P450 2B proteins. J Biol Chem 283:889-898.
13. Lee CM, Pohl J, and Morgan ET (2009) Dual mechanisms of CYP3A protein regulation by proinflammatory cytokine stimulation in primary hepatocyte cultures. Drug Metab Dispos 37:865-872.
14. Lee DH and Goldberg AL (1998) Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 8:397-403.
15. McKee CM, Lowenstein CJ, Horton MR, Wu J, Bao C, Chin BY, Choi AM, and Noble PW (1997) Hyaluronan fragments induce nitric-oxide synthase in murine macrophages through a nuclear factor κB-dependent mechanism. J Biol Chem 272:8013-8018.
16. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454:428-435.
17. Mellits KH, Hay RT, and Goodbourn S (1993) Proteolytic degradation of MAD3 (IκBα) and enhanced processing of the NF-κB precursor p105 are obligatory steps in the activation of NF-κB. Nucleic Acids Res 21:5059-5066.
18. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, and Crews CM (1999) Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96:10403-10408.
19. Miyamoto S, Chiao PJ, and Verma IM (1994) Enhanced IκBα degradation is responsible for constitutive NF-κB activity in mature murine B-cell lines. Mol Cell Biol 14:3276-3282.
20. Myung J, Kim KB, and Crews CM (2001) The ubiquitin-proteasome pathway and proteasome inhibitors. Med Res Rev 21:245-273.
21. Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, and Miwa G (2005) Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites. Drug Metab Dispos 33:771-777.
22. Strom SC, Pisarov LA, Dorko K, Thompson MT, Schuetz JD, and Schuetz EG (1996) Use of human hepatocytes to study P450 gene induction. Methods Enzymol 272:388-401. (Pubitemid 26299903)
23. Sueyoshi T and Negishi M (2001) Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu Rev Pharmacol Toxicol 41:123-143.
24. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, et al. (2003) The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9:220-224.
25. Uttamsingh V, Lu C, Miwa G, and Gan LS (2005) Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 33:1723-1728.
26. Wang HF, Figueiredo Pereira ME, and Correia MA (1999) Cytochrome P450 3A degradation in isolated rat hepatocytes: 26S proteasome inhibitors as probes. Arch Biochem Biophys 365:45-53.
27. Werner ED, Brodsky JL, and McCracken AA (1996) Proteasome-dependent endoplasmic reticulum-associated protein degradation: an unconventional route to a familiar fate. Proc Natl Acad Sci USA 93:13797-13801.